Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 681 of 5804
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a phone app and 800-Calorie diet reverse type 2 diabetes?
Disease control CompletedThis is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered remotely) is more likely to lead to weight loss and…
Phase: NA • Sponsor: Habitual Health Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control CompletedThe purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, si…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for hard-to-treat lung cancer: drug combo aims to shrink tumors
Disease control OngoingThis multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins mutation. This study is investigating the safety a…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Triple therapy targets tough lung cancer
Disease control OngoingA phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a kidney cell injection slow Diabetes-Related kidney failure?
Disease control Recruiting nowThe purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.
Phase: PHASE3 • Sponsor: Prokidney • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to outperform standard drugs for rare blood cancer
Disease control Recruiting nowThis phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Custom-Made vaccine aims to stop prostate cancer recurrence
⭐️ VACCINE ⭐️ OngoingThis proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor free adjuvant setting.
Phase: PHASE1 • Sponsor: Ashutosh Kumar Tewari • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
-
New targeted pill shows promise for Hard-to-Treat lung cancers
Disease control Recruiting nowPhase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced R…
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Implantable device could offer new hope for patients with untreatable chest pain
Disease control Recruiting nowTo demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribut…
Phase: NA • Sponsor: Shockwave Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot aims to slash COPD attacks in former smokers
Disease control CompletedThe purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Parti…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Hope for rare nerve disease: new drug targets toxic sugar buildup
Disease control CompletedThis study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.
Phase: PHASE2, PHASE3 • Sponsor: Applied Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
Disease control CompletedThis retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with mo…
Sponsor: Charles University, Czech Republic • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a Double-Dose of antibiotics in bone cement prevent infections after hip surgery?
Disease control OngoingRational for conducting the study: Periprosthetic joint infection (PJI) is the most feared complication following prosthetic replacement of the hip joint and is associated with increased mortality, morbidity and economic burden. The aim of the trial is to investigate whether the …
Phase: PHASE3 • Sponsor: Umeå University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced…
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common asthma drug help newborns breathe easier?
Symptom relief OngoingClinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn (TTN).
Phase: PHASE3 • Sponsor: Medical University of Warsaw • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Spinal zap + breathing drills may restore lung power after paralysis
Symptom relief Recruiting nowRespiratory motor control deficit is the leading cause of morbidity and mortality in patients with spinal cord injury. The long-term goal of this NIH-funded study is to develop a rehabilitation strategy for respiration in patients with spinal cord injury as a standard of care. Re…
Phase: NA • Sponsor: University of Louisville • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail targets tough lung cancer mutation
Disease control CompletedThe purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Phase: PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for liver cancer: drug combo trial launches
Disease control ENROLLING_BY_INVITATIONThis study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd characteristics, and determine the treatment plan o…
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill shows promise against rare brain cancer
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/ritu…
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC